Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2014; 20(31): 10715-10728
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10715
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10715
Clinical mycophenolic acid monitoring in liver transplant recipients
Hao Chen, Center of Organ Transplantation and Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China
Bing Chen, Institute of Clinical Pharmacology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Author contributions: Chen H and Chen B performed and wrote the paper; Chen H designed and performed the review.
Correspondence to: Hao Chen, PhD, Center of Organ Transplantation and Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Erlu, Shanghai 200240, China. haochendr@126.com
Telephone: +86-21-64370045 Fax: +86-21-64333548
Received: September 17, 2013
Revised: June 3, 2014
Accepted: June 26, 2014
Published online: August 21, 2014
Processing time: 337 Days and 7.7 Hours
Revised: June 3, 2014
Accepted: June 26, 2014
Published online: August 21, 2014
Processing time: 337 Days and 7.7 Hours
Core Tip
Core tip: We discussed the methods of mycophenolic acid (MPA) monitoring, pharmacokinetic characteristics, clinical exposure related to acute rejection and mycophenolate mofetil (MMF) associated side effects in liver transplant recipients. We also introduced the methods of limited sampling strategies to predict the MPA area under the concentration-time curve. It demonstrated that a fixed-dosage MMF regimen might not be suitable. In clinical settings, monitoring of MPA exposure seems reasonable and necessary.